테브펜피라드

LC50; Species: Carp; Concentration: 0.073 mg/L for 48 hr /Conditions of bioassay not specified in source examined/

LD50; Species: Colinus virginianus (Bobwhite quail) oral >2000 mg/kg

LC50; Species: Anas platyrhyncos (Mallard duck) dietary >5000 mg/kg for 8 days

LC50; Species: Colinus virginianus (Bobwhite quail) dietary >5000 mg/kg for 8 days

LC50; Species: Baetis rhodani (Mayfly); Conditions: freshwater, static, 15 °C, pH 7.4, hardness 180 mg/L CaCO3; Concentration: 2.69 ug/L for 48 hr (95% confidence interval: 1.41-5.12 ug/L) /100% purity/

TERRESTRIAL FATE: Based on a classification scheme(1), reported Koc values of 1380 to 8310(2), indicate that tebufenpyrad is expected to have low to no mobility in soil(SRC). Volatilization of tebufenpyrad from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of <1.2X10-8 atm-cu m/mole(SRC), based upon its vapor pressure, <7.3X10-8 mm Hg(3), and water solubility, 2.61 mg/L(2). Tebufenpyrad is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(3). Specific biodegradation data were unavailable, but tebufenpyrad had reported soil dissipation half-lives in laboratory studies of 19 to 56 days and in the field as 2 to 50 days(2).

AQUATIC FATE: Based on a classification scheme(1), reported Koc values of 1380 to 8310(2), indicate that tebufenpyrad is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of <1.2X10-8 atm-cu m/mole(SRC), derived from its vapor pressure, <7.3X10-8 mm Hg(4), and water solubility, 2.61 mg/L(2). According to a classification scheme(5), an estimated BCF of 830(SRC), from its log Kow of 4.93(2) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is high(SRC). Microbially-mediated degradation has been identified as a major route of dissipation for tebufenpyrad(4). Tebufenpyrad is reported to be stable to hydrolysis at environmental pHs and has an aqueous photolysis half-life of 187 days at pH 7 and 25 °C(2).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), tebufenpyrad, which has a vapor pressure of <7.3X10-8 mm Hg at 20 °C(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase tebufenpyrad may be removed from the air by wet or dry deposition(SRC).

Tebufenpyrad residues were detected in 12 of 86 apple samples taken during a study of pesticides in agricultural products in Hyogo Prefecture, Japan from 1995 to 1999. Five of these residues were detected at <0.01 ug/g, five were detected at 0.01 to <0.05 ug/g and two were detected at 0.05 to <0.1 ug/g(1).

/GENOTOXICITY/ /In/ in vitro cytogenetics assays with human lymphocytes tebufenpyrad /at concentrations of/ a)6, 8, 20, 40, 60, 80 ug/mL for 21 hours without activation and 8.25, 11, 27.5, 55, 82.5, 110 ug/mL for 4 hours with activation /or/ b)6.25, 12.5, 25 :g/ml for 2 hours without activation and 12.5, 25 and 50 ug/mL for 3 hours with activation, the combined data from both studies indicate that without S9 activation, tebufenpyrad induced variable but nevertheless reproducible significant increases in the percentage of aberrant cells in two of three experiments using treatment times of 20-24 hours. In general, levels causing < 40% decrease in the MI /mitotic index/ were negative, whereas concentrations causing >42% decrease in the MI induced significant effects with reproducibly flat dose response curves. Furthermore, the same type of aberrations (chromatid breaks) was induced in both studies. Based on these considerations, it is concluded that MK-239 exhibited reproducible but weak evidence of a clastogenic response but only after prolonged exposure to cytotoxic doses and only in the absence of S9 activation. /from table/

An estimated BCF of 830 was calculated in fish for tebufenpyrad(SRC), using a log Kow of 4.93(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is high(SRC).

The Henry's Law constant for tebufenpyrad is estimated as <1.2X10-8 atm-cu m/mole(SRC) derived from its vapor pressure, <7.3X10-8 mm Hg(1), and water solubility, 2.61 mg/L(2). This Henry's Law constant indicates that tebufenpyrad is expected to be essentially nonvolatile from water and moist soil surfaces(3). Tebufenpyrad is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(1).

/LABORATORY ANIMALS: Acute Exposure/ Non-irritating to skin and eyes (rabbits). Sensitizing to skin (guinea pigs).

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ A uniform picture emerges for 90-day dietary or gavage studies in rats, mice and dogs. The only effects consistently observed were decreased weight gain and increased liver weight at the highest doses (about 28 mg/kg/day in the rat, 160 (M) to 220 (F) mg/kg/day in mice , and 10 mg/kg/day in dogs). Some liver hypertrophy was seen in rats, and vomiting and diarrhea occurred in dogs.

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Chronic toxicity in dogs /was studied at doses of/ 0, 1, 6, 20 mg/kg/day. NOAEL in males and females = 1 mg/kg/day; LOAEL = 6 mg/kg/day based on increased incidence of vomiting and diarrhea/loose stools and thickened gastric mucosa and chronic gastritis in the pyloric region. /from table/

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Chronic toxicity/carcinogenicity in rats /was studied at doses of/ 0, 5, 20, 150, or 300 ppm (M; 0, 0.21, 0.82, 6.52, 13.43 mg/kg/day: F: 0, 0.26, 1.01, 8.13, 16.95 mg/kg/day). ...Male rats had a significant increasing trend, and a significant difference in the pair-wise comparison of the 300 ppm dose group with the controls, for hepatocellular adenomas, both at p<0.01. The incidence at the high dose (300 ppm) exceeded the historical control range. ...The increase in benign liver tumors /was considered/ to be treatment-related in males. No hepatocellular carcinomas were observed in any group, including controls. Female rats had a significant increasing trend, and a significant difference in the pair-wise comparison of the 150 ppm dose group with the controls, for hepatocellular adenomas, both at p<0.05. However, no dose-related increase in these tumors was noted at the high dose (300 ppm). The incidence at 150 ppm was just outside the historical control range; and the incidence at 300 ppm was within the historical control range. No hepatocellular carcinomas were observed in any group, including controls. /from table/

For more Non-Human Toxicity Excerpts (Complete) data for TEBUFENPYRAD (8 total), please visit the HSDB record page.

Used as acaricide to protect cotton, citrus, fruits, vegetables, and ornamentals; [Merck Index] Registered for use on ornamentals in greenhouses; [Reference #1]

Farming (Pesticides) [Category: Industry]

For tebufenpyrad (USEPA/OPP Pesticide Code: 090102) ACTIVE products with label matches. /SRP: Registered for use in the U.S. but approved pesticide uses may change periodically and so federal, state and local authorities must be consulted for currently approved uses./

Acaricide/Miticide

Tebufenpyrad is registered for use on ornamental plants grown in commercial greenhouses.

Control of all stages of Tetranychus, Panonychus, Oligonychus and Eotetranychus spp.

Trade names: Masai, Pyranica

Emulsifiable concentrate, emulsion oil in water, water dispersible granule, wettable powder.

Trade names: Comanché; Oscar; Acarifas.

Types of Formulations: 98.9% technical product; 34.6% EC /emulsifiable concentrate/ end-use product.

For more Formulations/Preparations (Complete) data for TEBUFENPYRAD (6 total), please visit the HSDB record page.

Acaricides

Environmental transformation -> Pesticides (parent, predecessor)